Biopharma group declares win against Janssen

An Irish biopharma company says it has received a final award in its dispute with Janssen Pharmaceuticals over the licensing of nanotechnology for the treatment of schizophrenia and HIV, which will enable it to obtain US$425 million in additional revenue.

Unlock unlimited access to all Global Arbitration Review content